<DOC>
	<DOCNO>NCT02051361</DOCNO>
	<brief_summary>Coronary artery stent , particularly drug-eluting stent ( DES ) , use majority patient undergo percutaneous coronary intervention ( PCI ) improve symptom patient obstructive coronary artery disease . They function prevent abrupt closure stented artery soon procedure well low need repeat revascularization compare balloon angioplasty alone . Stent restenosis stent thrombosis potential complication coronary artery stenting ; incidence high first year PCI . Stent restenosis , occur frequently bare metal stent ( BMS ) DES , may occasionally present acute myocardial infarction ( MI ) . Stent thrombosis uncommon serious complication often present death almost always accompany MI , usually ST-segment elevation . Patients commonly treat dual antiplatelet therapy ( DAPT ) recommend duration particular stent . DAPT ( aspirin plus platelet P2Y12 receptor blocker ) significantly lower risk stent thrombosis .</brief_summary>
	<brief_title>Antiplatelet Therapy Following Stent Implantation</brief_title>
	<detailed_description>New Guidance Antiplatelet Therapy After Stenting : Clinical Advisory , Kirsten E. Fleischmann , MD , MPH review Grines CL et al . Circulation 2007 Feb 13 . An expert panel recommend 12 month therapy placement drug-eluting stent . Aspirin clopidogrel commonly prescribe placement bare metal stent drug-eluting stent . However , recent concern stent thrombosis ( Journal Watch Jan 4 2007 ) lead expert multiple group , include American Heart Association American College Cardiology , issue advisory preventing premature discontinuation dual antiplatelet therapy . Based review literature , expert offer observation recommendation include follow : - Dual antiplatelet therapy aspirin thienopyridine clopidogrel reduces cardiac event coronary stenting . - Premature discontinuation agent greatly increase risk stent thrombosis associate clinical event myocardial infarction death . - Patients receive 12 month dual antiplatelet therapy placement drug-eluting stent . - Elective surgery associate significant risk bleeding postpone appropriate course dual antiplatelet therapy ( i.e. , 1 month bare metal stent 12 month drug-eluting stent ) complete . - Patients ' ability comply prolong dual antiplatelet therapy need subsequent invasive procedure consider choose type stent . - Patients provider consult patient 's cardiologist stop dual therapy . Endpoints : Primary endpoint - Outcome Measures : 1 . Major Cardiovascular event 1 , 3 , 6 , 12 month study enrolment - All Death , - Cardiac death , - Myocardial infarction , - Stroke , - Target vessel revascularization - Bleeding event - In-stent restenosis ( ISR ) - Angiographical Determination Binary Stenosis Rate ( define diameter stenosis least 50 % stent / persistent area , 6 , 9 , 12 month stent implantation ) The angiographical determination degree stenosis , define percentage diameter stenosis stent /or persistent area , 6 12 month stent implantation . - The angiographical determination minimal lumen diameter stent / persistent area , 6 month stent implantation . Secondary : - Description report AE/ SAE per study subgroup . - Description miss dos per study subgroup . Study Medication : Category : ADP-P2Y12 interaction blokers - Clopidogrel ( Clovelen® ) - Dosage : As per Clopidogrel ( Clovelen® ) SmPC Study Concomitant Medication : Aspirin . DAT = Dual antiplatelet therapy consist aspirin add clopidogrel</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<criteria>Patients plan unplanned stent implantation Ages Eligible Study : 18 Years old Genders Eligible Study : Both Acute coronary syndrome STsegment elevation MI ( STEMI ) non STsegment elevation MI ( STEMI ) Stable angina pectoris or/ document myocardial ischemia Instable angina pectoris or/ document myocardial ischemia Denovo stenosis coronary artery degree stenosis 50 % 99 % , accessible PTCA Patients predefined group clopidogrel treatment DES implantation Willingness ability adhere study condition Written inform consent patient information Known severe arrhythmia necessitate long term antiarrhythmic therapy Pericarditis Intracardiac thrombus Bacterial endocarditis Patients contraindication aortocoronary bypass operation , Contraindication antiplatelet therapy Noncardiac comorbid condition may result protocol noncompliance ( per site investigator 's medical judgment ) . Bleeding diathesis Thrombocytopenia ( &lt; 150 000/mm3 ) Recent ( &lt; 6 month ) gastrointestinal bleed Recent stroke within 6months Concurrent organ damage ( creatinine level &gt; 2.0mg/dL AST ALT &gt; 3 time upper normal reference value ) Patients leave main stem stenosis ( &gt; 50 % visual estimate ) History allergy aspirin Inability , understand sense purpose study Patients willing keep condition study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>DAT = Dual Antiplatelet Treatment</keyword>
	<keyword>Major Cardiac Adverse Events</keyword>
</DOC>